Xinji's 2017 financial report: lenalidomide's huge sale of $8.2 billion pounds, ozanimod is expected to go public in 2018

Source: medical data magic cube January 25, 2018, Xinji announced its 2017 performance, achieving a total revenue of US $13.03 billion, an increase of 15.8% compared with 2016 In 2017, the R & D investment of new base increased significantly, reaching US $5.915 billion, an increase of 32.3%, accounting for 45.5% of the total revenue Xinji expects total revenue of US $14.4-14.8 billion (+ 15%) in 2018 From the perspective of income composition, multiple myeloma, myelodysplastic syndrome and other blood tumors are the dominant businesses of new base Four drugs, including Revlimid, pomalyst, vidaza and thalidomide, contribute 81% of the sales revenue Xinji just bought impact biomedicals for us $7 billion (see: Xinji bought impact biomedicals for us $7 billion, only for fedratinib, which was abandoned by Sanofi), partner Juno for us $9 billion (see: Xinji bought Juno for us $9 billion), and partner Bluebird (see: 56% fully relieved! Blue bird car-t therapy bb2121 amazing ash2017), in multiple myeloma, myelofibrosis and other blood diseases product line is very strong New base 2017 drug sales (US $100 million) Revlimid (lenalidomide) increased by 17% in 2017, reaching US $8.187 billion, thanks to the expansion of the market and the increase of medication schedule (promoted to MM first-line medication) If this growth rate is in line with the forecast of fierce Pharma, it will become the world's largest cancer drug sales in 2022, reaching the level of 13.4 billion US dollars (see: top 15 cancer drugs in 2022: giant of running water, Roche of Tieda) Otezla (apopst) grew by 25.8% in 2017, with a very impressive growth rate as cosentyx and stellara Psoriasis and other autoimmune diseases is a very good market, the demand is increasing The products of concern in the new pipeline include car-t therapy bb2121, which is used to treat relapsed or refractory multiple myeloma It has been awarded breakthrough drug by FDA and priority drug by EMA Juno's car-t therapy jcar017 is expected to be approved in 2019 Fedratinib, a JAK2 inhibitor purchased from impact biomedicines, will apply for listing in mid-2018 In the field of inflammation and autoimmune diseases, ozanimod, an oral S1P1 regulator obtained from receptos, was purchased by Xinji in 2015 for us $7.2 billion In December 2017, ozanimod submitted a listing application for the treatment of recurrent multiple sclerosis to FDA In 2018, Q1 plans to submit a listing application to EMA Ozanimod's predicted peak sales could exceed $6 billion